Meeting
2023 ASCO Annual Meeting
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
Presenter
Irene L.M. Reijers, MD
Netherlands Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
The Promise of Neoadjuvant Immunotherapy Across Solid Tumors
Track
Special Sessions
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02977052
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 101)
DOI
10.1200/JCO.2023.41.16_suppl.101
Abstract #
101
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Speaker: Christian U. Blank, MD, PhD
Videos & Slides
2020 ASCO Virtual Scientific Program
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Speaker: Christian U. Blank, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Speaker: Christian U. Blank, MD, PhD
Videos & Slides
ASCO Media Events
Presentaion of LBA 2, Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Speaker: Christian Blank, MD, PhD